Try our Advanced Search for more refined results
Health
-
January 16, 2026
What To Watch For In 1st Paragard Bellwether Trial
Drugmaker Teva is set to face its first bellwether trial starting Tuesday in a multidistrict litigation containing thousands of claims that the Paragard copper IUD was prone to breaking and leaving pieces inside patients' uteri. Here, Law360 previews a trial that's shaping up to be a science-heavy battle of the experts.
-
January 16, 2026
Immigrant Visa Pause Could Test Limits Of Executive Power
The Trump administration's indefinite pause on immigrant visas for applicants from 75 countries may test the outer bounds of executive control over visa issuance and prompt court battles in a rarely litigated area of immigration law.
-
January 16, 2026
DOJ Reports Historic $6.8B False Claims Act Haul In 2025
The U.S. Department of Justice secured more than $6.8 billion via settlements and judgments under the False Claims Act in the fiscal year that ended September 2025, the largest amount recovered in a single year in the history of the FCA, the DOJ said Friday.
-
January 16, 2026
PBMs Seek Exit From Philly's Suit Over Opioid Crisis
CVS Health Corp. and other pharmacy benefit managers asked a Pennsylvania federal judge to let them out of the city of Philadelphia's lawsuit claiming they contributed to the opioid epidemic in the city, arguing that the city waited too long to file its suit and lacked standing to sue the companies.
-
January 16, 2026
Labcorp Reaches Settlement In Data Privacy Action
Labcorp has reached a settlement with internet users in a proposed class action in North Carolina federal court claiming that the clinical testing company sold users' data without their consent to Meta/Facebook and other tech giants.
-
January 16, 2026
Planned Parenthood Can Challenge Heartbeat Act, Court Says
A Texas appeals court on Friday found that Planned Parenthood has standing to challenge the state law that empowers ordinary citizens to prosecute abortion providers, saying Planned Parenthood has done enough to launch a pre-enforcement challenge to the law.
-
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
Biotech company Lifecore Biomedical Inc. has reached a $3.8 million deal with its investors to end their claims the company had weak controls over its financial reporting, impairing its ability to remain compliant with Nasdaq listing requirements and causing share declines.
-
January 16, 2026
NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.
-
January 16, 2026
Oversight Head Seeks Help From CMS On NY Medicaid Inquiry
House Oversight and Government Reform Committee Chair James Comer, R-Ky., asked the Centers for Medicare & Medicaid Services on Friday to aid the committee's investigation into whether New York has wrongfully withheld funds for hospitals disproportionately serving Medicaid recipients and uninsured people.
-
January 16, 2026
Walgreens Workers Snag $2.5M Deal To End Late Pay Suit
Walgreens has agreed to pay $2.5 million to a class of workers who accused the pharmacy chain of not paying their final paychecks on time, the workers said Friday, urging an Oregon federal court to greenlight the settlement.
-
January 16, 2026
Acadia Investors Get Initial OK For $179M Settlement
Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.
-
January 16, 2026
Taxation With Representation: Stibbe, A&O Shearman, Latham
In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.
-
January 16, 2026
Class Cert. Recommended For Nurses In Holiday Pay Case
A group of nurses should proceed as a class in a suit accusing a healthcare company of excluding holiday premiums from their pay when they worked overtime, a Colorado magistrate judge found.
-
January 16, 2026
La. State Court Greenlights Challenge To Gender Care Ban
A Louisiana state judge sided with a group of transgender teenagers who argue the state's ban on gender-affirming care for minors is unconstitutional, denying the state's bid to dismiss the case, according to an announcement Friday from the minors' attorneys.
-
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
The U.S. Supreme Court agreed Friday to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent case over its "skinny label" on a generic heart drug, after the Trump administration urged the court to take the case.
-
January 16, 2026
UK Litigation Roundup: Here's What You Missed In London
This past week in London saw the David Lloyd gym chain file an intellectual property claim against its founder, security company Primekings reignite a long-running dispute with the former owners of an acquired business, and a pair of Belizean developers sue a finance executive they say shut them out of a cruise port project.
-
January 16, 2026
Widower Of BNY Mellon Bank VP Says Hospital Missed Cancer
Doctors at Allegheny Health Network missed indications that a BNY Mellon vice president's stomach ulcers were a sign of cancer and didn't correctly diagnose her until it had spread throughout her abdomen, according to a lawsuit filed in Pennsylvania state court by her widower Wednesday.
-
January 15, 2026
SEC Says Healthcare Exec Misspent $10.6M In Investor Funds
The U.S. Securities and Exchange Commission on Thursday accused a healthcare company CEO of misappropriating over $10 million from investors by falsely claiming the funds would be used to develop cancer screening and treatment technology when in fact they were spent on credit card debt, luxury vehicles and strip club visits.
-
January 15, 2026
Wrong Word Dooms Med Mal Suit Against UT Cancer Center
A Texas appeals court on Thursday dismissed a suit accusing the University of Texas M.D. Anderson Cancer Center of causing a cancer patient's injuries from "chemotherapy," saying that because the treatment was actually "immunotherapy," an exception to governmental immunity did not apply.
-
January 15, 2026
3 Brothers Used Dental Practices To Bilk Medicare, Jury Told
Federal prosecutors told a Pennsylvania jury on Thursday that brothers operating a nationwide chain of dental practices were the driving force of a complex scheme that the government said defrauded Medicare through bogus reimbursement claims, the use of unapproved dental implants and the fudging of visa paperwork to recruit foreign workers.
-
January 15, 2026
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading
New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.
-
January 15, 2026
Trial 'No Longer Warranted' After Judge's Stelara Reversal
The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia federal judge reversed course and nixed key claims he had previously teed up for trial.
-
January 15, 2026
5th Circ. Revives Allstate's Fraud Suit Over Car Crash Billing
The Fifth Circuit on Wednesday revived Allstate's racketeering suit alleging doctors and personal injury lawyers unleashed a barrage of unnecessary treatments for car accident patients and caused Allstate to pay $4.7 million in claims, finding the insurer sufficiently pled details about the conspiracy and specifics surrounding each allegedly fake medical billing.
-
January 15, 2026
Trump Admin Defies Funding K-12 Mental Health Grants
The Trump administration is fighting an effort by a coalition of U.S. states to preserve at least six months of funding for K-12 mental health grants meant to help students process gun violence, arguing that an earlier court ruling doesn't require the feds to fund the grants.
-
January 15, 2026
Simpson Thacher Guides New Mountain's $1.2B Fund Close
New Mountain Capital LLC, guided by Simpson Thacher & Bartlett LLP, has closed its second noncontrol private equity fund with $1.2 billion raised, aiming to use the funds to target companies in industries such as healthcare technology and life sciences, the alternative investment firm announced on Thursday.
Expert Analysis
-
Steps For Healthcare Providers After Cigna ERISA Settlement
Following the Cigna class action's settlement, where Employee Retirement Income Security Act violations arose from Cigna's online provider directory advertising providers as in-network who were actually out-of-network, providers should routinely audit their contract status and directory listings, and proactively coordinate with plans and payor partners, say attorneys at ArentFox Schiff.
-
DOJ's UnitedHealth Settlement Highlights New Remedies Tack
The use of divestitures and Hart-Scott-Rodino Act compliance in the recent U.S. Department of Justice settlement with UnitedHealth Group and Amedisys underscores the DOJ Antitrust Division's willingness to utilize merger remedies under the second Trump administration, say attorneys at Buchanan Ingersoll.
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.
-
H-1B Fee Guidance Is Helpful But Notable Uncertainty Persists
Recent guidance narrowing the scope of the $100,000 entry fee for H-1B visas will allow employers to plan for the hiring season, but a lack of detail about the mechanics of cross-agency payment verification, fee exemptions and other practical matters still need to be addressed, say attorneys at Klasko Immigration Law Partners.
-
Risk Mitigation For Psychedelic Use In Reproductive Health
With the rising use of psychedelics among women of reproductive age and the absence of clear professional guidelines regarding risk labeling, healthcare providers and facilitators should adopt proactive, evidence-based approaches to mitigate malpractice liability risks, say Kimberly Chew at Husch Blackwell and Sara Shoar at the University of Southern California.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Adapting To Enforcement Focus On Wound Care Fraud
As federal agencies target wound care industry fraud as a top enforcement priority, attorneys advising industry stakeholders should evaluate business relationships for Anti-Kickback Statute violations, emphasize appropriate product use and documentation, and use internal data analytics to monitor billing patterns, say David Tarras at Tarras Defense and Jay McCormack at Verrill Dana.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
AG Watch: Illinois A Key Player In State-Level Enforcement
Illinois Attorney General Kwame Raoul has systematically strengthened his office to fill federal enforcement gaps, oppose Trump administration mandates and advance state policy objectives, particularly by aggressively pursuing labor-related issues, say attorneys at Troutman.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.
-
Organ Transplant System Reforms Mark Regulatory Overhaul
Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.
-
Federal Grantees May Soon Face More Limitations On Speech
If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.